<div id="readability-page-1"><div>Piekos Brian Chief Financial Officer of KalVista Pharmaceuticals Inc [KALV] filed a Form 4 on November 26, 2025 with the Securities and Exchange Commission disclosing the following changes in ownership:<div><table><tbody><tr><th>Date</th><th>Transaction</th><th>Shares</th><th>Price</th><th>Value</th></tr><tr><td>11/21/25</td><td>Exercise</td><td>15,000</td><td>$0.00</td><td>N/A</td></tr><tr><td>11/24/25</td><td>Surrender(1)</td><td>4,471</td><td>$13.45</td><td>$60,139</td></tr></tbody></table></div>Ending Holdings: 10,529 - Direct<ul><li>(1)</li><li>Surrender of shares back to company to pay option exercise cost and/or resulting tax liability.</li></ul>For a free trial, or to learn more about our insider trading analysis and data services, please visit http://www.washingtonservice.com or contact us at (301) 913-5100 or send an email to info@washingtonservice.com.Founded in 1970, The Washington Service provides securities professionals with financial, economic and public policy research and data. </div></div>

KALV

CFO Brian Piekos of KalVista Pharmaceuticals Inc filed a Form 4 with the SEC, disclosing changes in ownership. On November 21, 2025, he exercised 15,000 shares, and on November 24, 2025, surrendered 4,471 shares at $13.45 each to cover option exercise costs and tax liabilities. His ending holdings are 10,529 shares directly. The Washington Service offers insider trading analysis and data services.

CFO Piekos Acquires 10,529 Of KalVista Pharmaceuticals Inc [KALV]